Per protocol analysis of patients (n=20) who completed the 12-week study
| Baseline | Week 12 | p-value | |
| Haemoglobin g·dL−1 | 10.7±0.9 | 13.6±1.3 | <0.001# |
| Iron µmol·L−1 | 5.4±2.0 | 19.7±11.7 | <0.001# |
| Transferrin saturation % | 7.5±3.1 | 31.7±19.6 | <0.001# |
| Ferritin µg·L−1 | 13.1±6.7 | 36.6±19.8 | <0.001# |
| WHO FC | |||
| I | 0 (0) | 0 (0) | 0.091¶ |
| II | 4 (17) | 9 (45) | |
| III | 16 (83) | 11 (55) | |
| IV | 0 (0) | 0 (0) | |
| 6-min walk distance m | 331±147 | 381±131 | 0.004# |
| NT-proBNP ng·L−1 | 496 (254–902) | 298 (160–484) | 0.003# |
| Right atrial area cm2 | 23.7±8.4 | 23.3±8.3 | 0.070# |
| Right ventricular diastolic diameter (four-chamber view) mm | 45.4±8.9 | 42.3±8.4 | 0.050# |
| Right ventricular diastolic diameter (parasternal long axis) mm | 38.7±7.3 | 35.0±6.3 | 0.002# |
| Right ventricular fractional area change % | 30.5±12.8 | 37.0±11.3 | 0.005# |
| TAPSE mm | 21.6±5.6 | 21.3±5.6 | 1.000# |
Data are presented as mean±sd, n (%) or median (interquartile range), unless otherwise stated. WHO FC: World Health Organization functional class; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; TAPSE: tricuspid annular plane systolic excursion. #: nonparametric Wilcoxon test (paired); ¶: Chi-squared test.